-
Posted by
Two Blokes Jun 6 -
Filed in
Stock
-
13 views
Eton Pharmaceuticals is experiencing explosive rare-disease revenue growth, with a 117% YoY increase and a robust pipeline fueling future expansion. Despite a 400% share price surge, ETON remains attractively valued versus peers, offering high growth potential for risk-tolerant investors. Operational leverage is improving, and near-term catalysts—product launches, label expansions, and M&A—could drive further upside as profitability approaches.
